Skip to main content
Top
Published in: The International Journal of Cardiovascular Imaging 2/2014

01-12-2014 | Original Paper

Late gadolinium enhancement magnetic resonance imaging for the assessment of myocardial infarction: comparison of image quality between single and double doses of contrast agents

Authors: Yeo Koon Kim, Eun-Ah Park, Whal Lee, Sang Yoon Kim, Jin Wook Chung

Published in: The International Journal of Cardiovascular Imaging | Special Issue 2/2014

Login to get access

Abstract

To compare the image quality of late gadolinium enhancement (LGE) cardiac magnetic resonance imaging (CMR) using a single dose of gadolinium contrast agent versus the conventional double dose for assessing myocardial infarction. This retrospective study examined 37 patients with chronic myocardial infarction who underwent LGE CMR using both inversion recovery (IR)-turbo fast low-angle shot magnitude-reconstructed and phase-sensitive images with two different dosages of gadolinium contrast agent: a single dose of 0.1 mmol/kg gadolinium-DTPA in 17 patients and a double dose of 0.2 mmol/kg in 20 patients. The contrast-to-noise ratio (CNR) and visual conspicuity between infarct and normal myocardium (CNRinfarct-normal, conspicuityinfarct-normal) and between infarct and left ventricular cavity (CNRinfarct-LVC, conspicuityinfarct-LVC) were compared. Interobserver agreement for the maximal transmural extent of infarction was also evaluated. CNRinfarct-normal was significantly higher with double-dose gadolinium contrast agent (15.5 ± 20.7 vs. 40.4 ± 16.1 in magnitude images and 9.5 ± 2.8 vs. 11.2 ± 2.7 in phase-sensitive images, P < 0.001) while conspicuityinfarct-normal showed no significant difference between the two groups (P > 0.05). Both CNRinfarct-LVC (7.7 ± 10.7 vs. −6.6 ± 19.0 in magnitude images and 4.1 ± 2.3 vs. −0.4 ± 4.1 in phase-sensitive images, P < 0.05) and conspicuityinfarct-LVC were significantly better with single-dose gadolinium contrast. Interobserver agreement for assessing the transmural extent of infarction was moderate in both groups: 0.591 for single-dose and 0.472 for double-dose. LGE CMR using a single dose of gadolinium contrast agent showed significantly better contrast between infarcted myocardium and left ventricular cavity lumen without a significant decrease in visual contrast between infarcted myocardium and normal myocardium, compared to a double dose.
Literature
1.
go back to reference Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics C, Stroke Statistics S (2013) Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127(1):e6–e245 Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics C, Stroke Statistics S (2013) Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127(1):e6–e245
2.
go back to reference Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343(20):1445–1453PubMedCrossRef Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343(20):1445–1453PubMedCrossRef
3.
go back to reference Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM (1999) Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100(19):1992–2002PubMedCrossRef Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM (1999) Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100(19):1992–2002PubMedCrossRef
4.
go back to reference Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM (2000) Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 36(6):1985–1991PubMedCrossRef Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM (2000) Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 36(6):1985–1991PubMedCrossRef
5.
go back to reference Nacif MS, Arai AE, Lima JA, Bluemke DA (2012) Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson 14:18PubMedCentralPubMed Nacif MS, Arai AE, Lima JA, Bluemke DA (2012) Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson 14:18PubMedCentralPubMed
6.
go back to reference Kim RJ, Shah DJ, Judd RM (2003) How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5(3):505–514PubMedCrossRef Kim RJ, Shah DJ, Judd RM (2003) How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5(3):505–514PubMedCrossRef
7.
go back to reference Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley WG Jr, Froelich JW, Gilk T, Gimbel JR, Gosbee J, Kuhni-Kaminski E, Lester JW Jr, Nyenhuis J, Parag Y, Schaefer DJ, Sebek-Scoumis EA, Weinreb J, Zaremba LA, Wilcox P, Lucey L, Sass N, Safety ACRBRPoM (2007) ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188(6):1447–1474PubMedCrossRef Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley WG Jr, Froelich JW, Gilk T, Gimbel JR, Gosbee J, Kuhni-Kaminski E, Lester JW Jr, Nyenhuis J, Parag Y, Schaefer DJ, Sebek-Scoumis EA, Weinreb J, Zaremba LA, Wilcox P, Lucey L, Sass N, Safety ACRBRPoM (2007) ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188(6):1447–1474PubMedCrossRef
8.
go back to reference Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J (2009) Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 253(1):81–89PubMedCrossRef Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J (2009) Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 253(1):81–89PubMedCrossRef
9.
go back to reference Wagner A, Mahrholdt H, Thomson L, Hager S, Meinhardt G, Rehwald W, Parker M, Shah D, Sechtem U, Kim RJ, Judd RM (2006) Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47(10):2027–2033PubMedCrossRef Wagner A, Mahrholdt H, Thomson L, Hager S, Meinhardt G, Rehwald W, Parker M, Shah D, Sechtem U, Kim RJ, Judd RM (2006) Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47(10):2027–2033PubMedCrossRef
10.
go back to reference Durmus T, Schilling R, Doeblin P, Huppertz A, Hamm B, Taupitz M, Wagner M (2012) Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine. Invest Radiol 47(3):183–188PubMed Durmus T, Schilling R, Doeblin P, Huppertz A, Hamm B, Taupitz M, Wagner M (2012) Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine. Invest Radiol 47(3):183–188PubMed
11.
go back to reference Petersen SE, Mohrs OK, Horstick G, Oberholzer K, Abegunewardene N, Ruetzel K, Selvanayagam JB, Robson MD, Neubauer S, Thelen M, Meyer J, Kreitner KF (2004) Influence of contrast agent dose and image acquisition timing on the quantitative determination of nonviable myocardial tissue using delayed contrast-enhanced magnetic resonance imaging. J Cardiovasc Magn Reson 6(2):541–548PubMedCrossRef Petersen SE, Mohrs OK, Horstick G, Oberholzer K, Abegunewardene N, Ruetzel K, Selvanayagam JB, Robson MD, Neubauer S, Thelen M, Meyer J, Kreitner KF (2004) Influence of contrast agent dose and image acquisition timing on the quantitative determination of nonviable myocardial tissue using delayed contrast-enhanced magnetic resonance imaging. J Cardiovasc Magn Reson 6(2):541–548PubMedCrossRef
12.
go back to reference Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York, NY Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York, NY
13.
go back to reference Kramer MS, Feinstein AR (1981) Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 29(1):111–123PubMedCrossRef Kramer MS, Feinstein AR (1981) Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 29(1):111–123PubMedCrossRef
14.
go back to reference Braunwald E, Rutherford JD (1986) Reversible ischemic left ventricular dysfunction: evidence for the “hibernating myocardium”. J Am Coll Cardiol 8(6):1467–1470PubMedCrossRef Braunwald E, Rutherford JD (1986) Reversible ischemic left ventricular dysfunction: evidence for the “hibernating myocardium”. J Am Coll Cardiol 8(6):1467–1470PubMedCrossRef
15.
go back to reference Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H (1986) Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 314(14):884–888PubMedCrossRef Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H (1986) Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 314(14):884–888PubMedCrossRef
16.
go back to reference Perrone-Filardi P, Pace L, Prastaro M, Squame F, Betocchi S, Soricelli A, Piscione F, Indolfi C, Crisci T, Salvatore M, Chiariello M (1996) Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-h–24-h 201Tl tomography versus dobutamine echocardiography. Circulation 94(11):2712–2719PubMedCrossRef Perrone-Filardi P, Pace L, Prastaro M, Squame F, Betocchi S, Soricelli A, Piscione F, Indolfi C, Crisci T, Salvatore M, Chiariello M (1996) Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-h–24-h 201Tl tomography versus dobutamine echocardiography. Circulation 94(11):2712–2719PubMedCrossRef
17.
go back to reference Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M (1997) Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 96(3):793–800PubMedCrossRef Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M (1997) Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 96(3):793–800PubMedCrossRef
18.
go back to reference Chaudhry FA, Tauke JT, Alessandrini RS, Vardi G, Parker MA, Bonow RO (1999) Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 34(3):730–738PubMedCrossRef Chaudhry FA, Tauke JT, Alessandrini RS, Vardi G, Parker MA, Bonow RO (1999) Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 34(3):730–738PubMedCrossRef
19.
go back to reference Reimer KA, Lowe JE, Rasmussen MM, Jennings RB (1977) The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56(5):786–794PubMedCrossRef Reimer KA, Lowe JE, Rasmussen MM, Jennings RB (1977) The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56(5):786–794PubMedCrossRef
20.
go back to reference Hillenbrand HB, Kim RJ, Parker MA, Fieno DS, Judd RM (2000) Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. Circulation 102(14):1678–1683PubMedCrossRef Hillenbrand HB, Kim RJ, Parker MA, Fieno DS, Judd RM (2000) Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. Circulation 102(14):1678–1683PubMedCrossRef
21.
go back to reference Kellman P, Arai AE, McVeigh ER, Aletras AH (2002) Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med 47(2):372–383PubMedCentralPubMedCrossRef Kellman P, Arai AE, McVeigh ER, Aletras AH (2002) Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med 47(2):372–383PubMedCentralPubMedCrossRef
22.
go back to reference Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE (2004) Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol 43(12):2253–2259PubMedCrossRef Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE (2004) Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol 43(12):2253–2259PubMedCrossRef
23.
go back to reference Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM, Gadoversetamide Myocardial Infarction Imaging I (2008) Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 117(5):629–637PubMedCrossRef Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM, Gadoversetamide Myocardial Infarction Imaging I (2008) Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 117(5):629–637PubMedCrossRef
24.
go back to reference Setser RM, Chung YC, Weaver JA, Stillman AE, Simonetti OP, White RD (2005) Effect of inversion time on delayed-enhancement magnetic resonance imaging with and without phase-sensitive reconstruction. J Magn Reson Imaging 21(5):650–655PubMedCrossRef Setser RM, Chung YC, Weaver JA, Stillman AE, Simonetti OP, White RD (2005) Effect of inversion time on delayed-enhancement magnetic resonance imaging with and without phase-sensitive reconstruction. J Magn Reson Imaging 21(5):650–655PubMedCrossRef
25.
go back to reference Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, Finn JP, Judd RM (2001) An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218(1):215–223PubMedCrossRef Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, Finn JP, Judd RM (2001) An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218(1):215–223PubMedCrossRef
26.
go back to reference Gupta A, Lee VS, Chung YC, Babb JS, Simonetti OP (2004) Myocardial infarction: optimization of inversion times at delayed contrast-enhanced MR imaging. Radiology 233(3):921–926PubMedCrossRef Gupta A, Lee VS, Chung YC, Babb JS, Simonetti OP (2004) Myocardial infarction: optimization of inversion times at delayed contrast-enhanced MR imaging. Radiology 233(3):921–926PubMedCrossRef
27.
go back to reference Huber AM, Schoenberg SO, Hayes C, Spannagl B, Engelmann MG, Franz WM, Reiser MF (2005) Phase-sensitive inversion-recovery MR imaging in the detection of myocardial infarction. Radiology 237(3):854–860PubMedCrossRef Huber AM, Schoenberg SO, Hayes C, Spannagl B, Engelmann MG, Franz WM, Reiser MF (2005) Phase-sensitive inversion-recovery MR imaging in the detection of myocardial infarction. Radiology 237(3):854–860PubMedCrossRef
28.
go back to reference Huber A, Schoenberg SO, Spannagl B, Rieber J, Erhard I, Klauss V, Reiser MF (2006) Single-shot inversion recovery TrueFISP for assessment of myocardial infarction. AJR Am J Roentgenol 186(3):627–633PubMedCrossRef Huber A, Schoenberg SO, Spannagl B, Rieber J, Erhard I, Klauss V, Reiser MF (2006) Single-shot inversion recovery TrueFISP for assessment of myocardial infarction. AJR Am J Roentgenol 186(3):627–633PubMedCrossRef
Metadata
Title
Late gadolinium enhancement magnetic resonance imaging for the assessment of myocardial infarction: comparison of image quality between single and double doses of contrast agents
Authors
Yeo Koon Kim
Eun-Ah Park
Whal Lee
Sang Yoon Kim
Jin Wook Chung
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
The International Journal of Cardiovascular Imaging / Issue Special Issue 2/2014
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-014-0505-x

Other articles of this Special Issue 2/2014

The International Journal of Cardiovascular Imaging 2/2014 Go to the issue